<DOC>
	<DOCNO>NCT02211469</DOCNO>
	<brief_summary>The primary objective study ass single dose BMS-986104 safe , tolerable , result sufficient lymphopenia ( 50 % 70 % reduction absolute lymphocyte count ) achieve without bradycardia adverse event healthy male subject .</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled , Double-Blind , Single Ascending Dose Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics BMS-986104 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Healthy male subject determine medical history , physical examination , vital sign , 12lead electrocardiogram ( ECG ) , clinical laboratory evaluation eligible participate study Men age 18 49 year , inclusive Any acute chronic medical illness judge clinicallysignificant Investigator and/or Sponsor medical monitor Presence fecal occult blood screen History prolong occupational exposure organic solvent pesticide History vitamin B12 deficiency and/or achlorhydria ; vitamin B12 level screen &lt; low limit normal ( LLN ) , confirm repeat test History GuillainBarré Syndrome Past current history central peripheral neuropathy , past current symptom sustain recurrent paresthesia ( tingle ) , numbness , neuropathic pain ( burning , ache stab ) extremity . Note : Experiencing extremity `` fall asleep '' occasionally exclusionary Clinically significant abnormality neurological exam baseline ( predose ) Clinically significant nerve electrophysiology abnormality baseline ( predose ) Any history testicular epididymal disease/disorder Clinically significant abnormality ophthalmologic exam finding suggest increase risk macular edema baseline ( predose ) History hypothyroidism carpal tunnel syndrome Subjects history diabetes mellitus Subjects history type heart disease , include ischemia , infarction , arrhythmia , hypertension , atrioventricular block degree , bradycardia , syncope , clinically significant ECG abnormality , congenital heart disease Subjects acute chronic bacterial , fungal viral infection within last 3 month prior screen , well febrile illness unknown origin within 14 day screen Subjects receive live vaccine within 1 month study drug administration plan live vaccine time study Positive test tuberculosis screening ( QuantiFERON® GOLD )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>